Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
2.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317-5. doi: 10.1016/j.kint.2019.02.033. [Epub ahead of print]

PMID:
31142441
3.

Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Siwy J, Klein T, Rosler M, von Eynatten M.

Proteomics Clin Appl. 2019 Mar;13(2):e1800144. doi: 10.1002/prca.201800144. Epub 2019 Jan 28.

PMID:
30632692
4.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
5.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

6.

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M.

J Hypertens. 2019 Jun;37(6):1294-1300. doi: 10.1097/HJH.0000000000002032.

PMID:
30540657
7.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
8.

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.

Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, Koitka-Weber A.

J Diabetes Investig. 2019 May;10(3):760-770. doi: 10.1111/jdi.12971. Epub 2019 Jan 7.

9.

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Wanner C, von Eynatten M, Zinman B.

Circulation. 2018 Aug 21;138(8):850-851. doi: 10.1161/CIRCULATIONAHA.118.035881. No abstract available.

PMID:
30359123
10.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
11.

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.

Bjornstad P, Laffel L, Tamborlane WV, Simons G, Hantel S, von Eynatten M, George J, Marquard J, Cherney DZI.

Diabetes Care. 2018 Aug;41(8):e129-e130. doi: 10.2337/dc18-0394. Epub 2018 Jun 25. No abstract available.

PMID:
29941496
12.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

13.

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.

Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, von Eynatten M, Okamura T.

Diabetes Ther. 2018 Apr;9(2):863-871. doi: 10.1007/s13300-018-0385-5. Epub 2018 Feb 27.

14.

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial.

Ma RC, Del Prato S, Gallwitz B, Shivane VK, Lewis-D'Agostino D, Bailes Z, Patel S, Lee J, von Eynatten M, Di Domenico M, Ross SA.

J Diabetes Investig. 2017 Sep 16. doi: 10.1111/jdi.12746. [Epub ahead of print]

15.

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators.

Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.

PMID:
28904068
16.

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, George JT, Rosenstock J.

Diabetes Care. 2017 Sep;40(9):1144-1151. doi: 10.2337/dc17-0068.

PMID:
28830955
17.

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.

PMID:
28666775
18.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.

19.

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Škrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZI.

Diabetologia. 2017 Jun;60(6):1159-1160. doi: 10.1007/s00125-017-4241-3. No abstract available.

PMID:
28374067
20.

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.

Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

21.

Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.

Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.

Postgrad Med. 2016 Nov;128(8):747-754. Epub 2016 Sep 29.

PMID:
27684308
22.

Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.

Del Prato S, Patel S, Crowe S, von Eynatten M.

Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):886-92. doi: 10.1016/j.numecd.2016.06.015. Epub 2016 Jul 1.

23.

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.

Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M.

Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2. Epub 2016 Jun 17.

PMID:
27316632
24.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators.

N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.

25.

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.

Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M.

Diab Vasc Dis Res. 2015 Nov;12(6):455-62. doi: 10.1177/1479164115579002. Epub 2015 Jul 28.

PMID:
26224765
26.

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.

Inzucchi SE, Nauck MA, Hehnke U, Woerle HJ, von Eynatten M, Henry RR.

Diabetes Obes Metab. 2015 Sep;17(9):868-77. doi: 10.1111/dom.12490. Epub 2015 Jun 27. Review.

PMID:
25974030
27.

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.

Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M.

Am J Kidney Dis. 2015 Sep;66(3):441-9. doi: 10.1053/j.ajkd.2015.03.024. Epub 2015 May 7.

28.

Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.

McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.

Diab Vasc Dis Res. 2015 Jul;12(4):249-57. doi: 10.1177/1479164115579001. Epub 2015 May 4.

PMID:
25941160
29.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.

Thrasher J, Kountz DS, Crowe S, Woerle HJ, von Eynatten M.

Postgrad Med. 2015 Jun;127(5):419-28. doi: 10.1080/00325481.2015.1027132. Epub 2015 Apr 3.

PMID:
25840727
30.

Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.

Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ.

Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684. No abstract available.

PMID:
25614693
31.

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.

Davidson JA, Lajara R, Aguilar RB, Mattheus M, Woerle HJ, von Eynatten M.

BMJ Open Diabetes Res Care. 2014 Apr 16;2(1):e000020. doi: 10.1136/bmjdrc-2014-000020. eCollection 2014.

32.

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.

Gallwitz B, Rosenstock J, Patel S, von Eynatten M, Hehnke U, Mehlburger L, Dugi KA, Woerle HJ.

Diabetes Obes Metab. 2015 Mar;17(3):276-84. doi: 10.1111/dom.12419. Epub 2015 Jan 9.

PMID:
25425502
33.

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M, Burns KD.

Kidney Int. 2014 Nov;86(5):1057-8. doi: 10.1038/ki.2014.246. No abstract available.

34.

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.

Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.

Diabetes Obes Metab. 2015 Feb;17(2):136-44. doi: 10.1111/dom.12399. Epub 2014 Nov 19.

PMID:
25298165
35.

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.

Skrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZ.

Diabetologia. 2014 Dec;57(12):2599-602. doi: 10.1007/s00125-014-3396-4. Epub 2014 Oct 4. No abstract available. Erratum in: Diabetologia. 2017 Jun;60(6):1159-1160.

PMID:
25280671
36.

Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.

Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.

Clin Ther. 2014 Nov 1;36(11):1595-605. doi: 10.1016/j.clinthera.2014.07.020. Epub 2014 Sep 16.

37.

Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246-254.

Graefe-Mody U, Friedrich C, von Eynatten M, Thiemann S, Heise T, Woerle HJ.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):417-8. doi: 10.1002/cpdd.119. Epub 2014 May 26. No abstract available.

PMID:
27129015
38.

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.

Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE.

Clin Ther. 2014 Aug 1;36(8):1130-46. doi: 10.1016/j.clinthera.2014.06.008. Epub 2014 Jul 8. Erratum in: Clin Ther. 2014 Nov 1;36(11):1705.

39.

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.

Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2014 Nov;16(11):1078-86. doi: 10.1111/dom.12321. Epub 2014 Jul 3.

PMID:
24865132
40.

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

Groop PH, Del Prato S, Taskinen MR, Owens DR, Gong Y, Crowe S, Patel S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2014 Jun;16(6):560-8. doi: 10.1111/dom.12281. Epub 2014 Mar 24.

41.

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC.

Cardiovasc Diabetol. 2014 Jan 29;13:28. doi: 10.1186/1475-2840-13-28.

42.

Linagliptin for elderly patients with type 2 diabetes - Authors' reply.

Barnett AH, von Eynatten M, Patel S, Woerle HJ.

Lancet. 2014 Jan 25;383(9914):307-8. doi: 10.1016/S0140-6736(14)60104-5. No abstract available.

PMID:
24461123
43.

Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes.

Kopf S, Oikonomou D, von Eynatten M, Kieser M, Zdunek D, Hess G, Morcos M, Forsblom C, Bierhaus A, Groop PH, Nawroth PP, Humpert PM.

Acta Diabetol. 2014;51(3):479-89. doi: 10.1007/s00592-013-0542-2. Epub 2013 Dec 24.

PMID:
24366425
44.

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M.

Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.

PMID:
24334175
45.

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, von Eynatten M, Woerle HJ.

Diab Vasc Dis Res. 2014 Jan;11(1):34-40. doi: 10.1177/1479164113507068. Epub 2013 Oct 29.

PMID:
24169807
46.

Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.

Int J Clin Pract. 2013 Dec;67(12):1283-93. doi: 10.1111/ijcp.12308. Epub 2013 Oct 9.

47.

Urinary n-acetyl-beta-d-glucosaminidase excretion: an indicator of neuropathy in type 2 diabetes.

Kopf S, Oikonomou D, Zdunek D, von Eynatten M, Hess G, Nawroth PP, Bierhaus A, Humpert PM.

Exp Clin Endocrinol Diabetes. 2013 Nov;121(10):601-6. doi: 10.1055/s-0033-1355384. Epub 2013 Sep 20.

PMID:
24057510
48.

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M.

Diabetes Care. 2013 Nov;36(11):3460-8. doi: 10.2337/dc13-0323. Epub 2013 Sep 11.

49.

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.

Lancet. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13.

PMID:
23948125
50.

Supplemental Content

Loading ...
Support Center